Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:MBIO NASDAQ:MDCX NASDAQ:NBRV NASDAQ:TELO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMBIOMustang Bio$1.67-5.9%$1.59$0.89▼$21.95$12.06M2.292.12 million shs148,294 shsMDCXMedicus Pharma$2.46-2.0%$2.27$1.79▼$8.94$43.83MN/A254,146 shs346,422 shsNBRVNabriva Therapeutics$0.00$1.22▼$8.45$45.46M1.5329,344 shsN/ATELOTelomir Pharmaceuticals$1.65-14.8%$1.47$1.12▼$7.08$53.10M-0.61.96 million shs2.31 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMBIOMustang Bio+1.72%+12.03%+20.41%-33.21%-83.61%MDCXMedicus Pharma+2.03%0.00%+20.10%-17.16%+250,999,900.00%NBRVNabriva Therapeutics0.00%0.00%0.00%0.00%+4,900.00%TELOTelomir Pharmaceuticals+16.97%+38.85%+41.91%+66.38%-60.04%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMBIOMustang Bio$1.67-5.9%$1.59$0.89▼$21.95$12.06M2.292.12 million shs148,294 shsMDCXMedicus Pharma$2.46-2.0%$2.27$1.79▼$8.94$43.83MN/A254,146 shs346,422 shsNBRVNabriva Therapeutics$0.00$1.22▼$8.45$45.46M1.5329,344 shsN/ATELOTelomir Pharmaceuticals$1.65-14.8%$1.47$1.12▼$7.08$53.10M-0.61.96 million shs2.31 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMBIOMustang Bio+1.72%+12.03%+20.41%-33.21%-83.61%MDCXMedicus Pharma+2.03%0.00%+20.10%-17.16%+250,999,900.00%NBRVNabriva Therapeutics0.00%0.00%0.00%0.00%+4,900.00%TELOTelomir Pharmaceuticals+16.97%+38.85%+41.91%+66.38%-60.04%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMBIOMustang Bio 1.00SellN/AN/AMDCXMedicus Pharma 2.83Moderate Buy$23.50832.54% UpsideNBRVNabriva Therapeutics 0.00N/AN/AN/ATELOTelomir Pharmaceuticals 2.67Moderate Buy$15.00806.34% UpsideCurrent Analyst Ratings BreakdownLatest MBIO, NBRV, MDCX, and TELO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025MBIOMustang BioWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025MDCXMedicus PharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025TELOTelomir PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/29/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$27.009/27/2025MBIOMustang BioWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025MDCXMedicus PharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025TELOTelomir PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/15/2025MDCXMedicus PharmaZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold9/2/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$27.008/22/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$27.008/13/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$27.00(Data available from 10/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMBIOMustang BioN/AN/AN/AN/A($2.11) per shareN/AMDCXMedicus PharmaN/AN/AN/AN/A$0.29 per shareN/ANBRVNabriva Therapeutics$35.59M0.00N/AN/A$0.10 per share0.00TELOTelomir PharmaceuticalsN/AN/AN/AN/A$0.02 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMBIOMustang Bio-$15.75M-$78.00N/AN/AN/AN/AN/A-29.49%11/6/2025 (Estimated)MDCXMedicus Pharma-$11.16M-$1.34N/AN/AN/AN/A-549.30%-228.06%11/28/2025 (Estimated)NBRVNabriva Therapeutics-$57.19M-$19.20N/AN/AN/A-148.11%-365.53%-135.81%N/ATELOTelomir Pharmaceuticals-$16.53M-$0.54N/AN/AN/AN/A-4,595.08%-1,750.91%11/11/2025 (Estimated)Latest MBIO, NBRV, MDCX, and TELO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025TELOTelomir Pharmaceuticals-$0.08-$0.17-$0.09-$0.17N/AN/A8/11/2025Q2 2025MDCXMedicus Pharma-$0.39-$0.43-$0.04-$0.43N/AN/A8/8/2025Q2 2025MBIOMustang BioN/A-$0.19N/A-$0.19N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMBIOMustang BioN/AN/AN/AN/AN/AMDCXMedicus PharmaN/AN/AN/AN/AN/ANBRVNabriva TherapeuticsN/AN/AN/AN/AN/ATELOTelomir PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMBIOMustang BioN/A1.301.30MDCXMedicus PharmaN/A1.291.29NBRVNabriva Therapeutics0.120.850.52TELOTelomir PharmaceuticalsN/A2.392.39Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMBIOMustang Bio9.95%MDCXMedicus PharmaN/ANBRVNabriva Therapeutics0.27%TELOTelomir PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipMBIOMustang Bio0.21%MDCXMedicus Pharma11.20%NBRVNabriva Therapeutics1.63%TELOTelomir PharmaceuticalsN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMBIOMustang Bio1007.24 million7.23 millionNot OptionableMDCXMedicus PharmaN/A17.82 million15.82 millionN/ANBRVNabriva Therapeutics7032.02 million31.49 millionNot OptionableTELOTelomir Pharmaceuticals132.28 millionN/AN/AMBIO, NBRV, MDCX, and TELO HeadlinesRecent News About These CompaniesTelomir says Telomir-1 selectively kills agressive TNBC cellsOctober 9 at 2:04 PM | msn.comTelomir stock soars after drug shows promise against aggressive breast cancerOctober 9 at 2:04 PM | za.investing.comWhy Telomir Pharmaceuticals Stock Is Rising 40% Premarket TodayOctober 9 at 9:03 AM | msn.comTelomir Pharmaceuticals Reports Discovery That Telomir-1 Selectively Kills Aggressive Triple-Negative Breast Cancer CellsOctober 9 at 7:30 AM | accessnewswire.comAWeiss Ratings Reiterates "Sell (E+)" Rating for Telomir Pharmaceuticals (NASDAQ:TELO)October 9 at 2:55 AM | marketbeat.comTelomir Pharmaceuticals Unveils Promising Cancer Treatment DiscoveryOctober 8 at 4:51 PM | tipranks.comTelomir stock soars after tumor suppressor gene reactivation resultsOctober 7 at 7:59 PM | investing.comTelomir Pharmaceuticals announces new findings in prostate cancer modelOctober 7 at 7:59 PM | msn.comTelomir shares surge after breakthrough tumor suppressor gene reactivation dataOctober 7 at 7:59 PM | msn.comTelomir Pharmaceuticals Announces New Findings in a Prostate Cancer Model Demonstrating Telomir-1 Also Resets DNA Methylation of Tumor Suppressor Genes Implicated in Two of the ...October 7 at 7:59 PM | usatoday.comTelomir Pharmaceuticals Announces New Findings in a Prostate Cancer Model Demonstrating Telomir-1 Also Resets DNA Methylation of Tumor Suppressor Genes Implicated in Two of the Most Persistent Challenges in Oncology-Metastasis and Treatment ResistanceOctober 7 at 7:30 AM | accessnewswire.comATelomir Pharmaceuticals, Inc. (NASDAQ:TELO) Sees Significant Decrease in Short InterestOctober 7 at 2:47 AM | americanbankingnews.comTelomir Pharmaceuticals’ Telomir-1 Shows Broad-Spectrum EfficacySeptember 18, 2025 | msn.comTelomir Pharmaceuticals announces in vitro data on Telomir-1September 18, 2025 | msn.comTelomir Pharmaceuticals Announces In Vitro Data Showing Telomir-1 Targets Additional Histone Demethylase Families, a Unique Profile in Cancer and Aging Not Seen in Other TherapiesSeptember 18, 2025 | accessnewswire.comATELO Releases Cancer Suppressing ResultsSeptember 9, 2025 | msn.comTelomir Pharmaceuticals announces preclinical cancer data on Telomir-1September 9, 2025 | msn.comTelomir Pharmaceuticals Announces New Cancer Data in Aggressive Human Prostate Cancer Cells Showing Telomir-1 Resets DNA Methylation to Reactivate CDKN2A, a Master Tumor ...September 9, 2025 | charlotteobserver.comCTelomir Pharmaceuticals Unveils Promising Preclinical Cancer DataSeptember 9, 2025 | tipranks.comTelomir Pharmaceuticals Announces New Cancer Data in Aggressive Human Prostate Cancer Cells Showing Telomir-1 Resets DNA Methylation to Reactivate CDKN2A, a Master Tumor Suppressor, Outperforming Rapamycin and ChemotherapySeptember 9, 2025 | accessnewswire.comATelomir Pharmaceuticals Completes $2.9 Million Stock SaleSeptember 4, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMBIO, NBRV, MDCX, and TELO Company DescriptionsMustang Bio NASDAQ:MBIO$1.66 -0.11 (-5.93%) As of 01:12 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-101 CAR T cell program for glioblastoma; MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.Medicus Pharma NASDAQ:MDCX$2.46 -0.05 (-1.99%) As of 12:51 PM EasternMedicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.Nabriva Therapeutics NASDAQ:NBRVNabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.Telomir Pharmaceuticals NASDAQ:TELO$1.64 -0.29 (-14.77%) As of 01:13 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Amazon’s Prime Day May Be the Catalyst for a Year-End Rally How Gamers Are Powering Microsoft’s Next Wave of Growth AI Meets Nuclear: Palantir’s Role in Energy Expansion Buy the Dip? Zillow’s Profit Comeback Meets Market Pressure Adobe Launches Premiere Pro on iPhone, Upside Ahead? Rocket Lab: A Space Giant Hitting New Highs—Time to Chase? After AI Hyperscaler Deal, Is Aehr Test Systems Stock on Sale? Why Archer Aviation Stock Is Soaring—And What Comes Next Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
